Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03585348 · ClinicalTrials.gov registry record
Provider Variability in the Use of Neuromuscular Blocking Drugs and Reversal
A clinical trial, sponsored by Beth Israel Deaconess Medical Center.
- Completed
- Registry status
- 265,537
- Enrollment target
NCT03585348 is a clinical trial that has completed, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 265,537 participants.
The verdict
NCT03585348 has completed, sponsored by Beth Israel Deaconess Medical Center.
- COMPLETED
- Registry status
- 265,537 participants
- Enrollment target
Study Summary
The use of neuromuscular blocking agents during surgery is associated with postoperative respiratory complications and increased risk of readmission to the hospital following ambulatory surgery. Understanding the clinical behavior of providers is essential in devising and assessing quality improvement projects since it is primarily individuals who determine the utilization of neuromuscular blocking drugs and reversal agents, not institutions. Therefore, the primary objective of this study is to determine the variability between individual anesthesia providers (attending physician, resident, nurse anesthetists) in the use of neuromuscular blocking drugs and reversal agents, using advanced statistical methods to adjust for differences in patient and procedure case mix. The investigators hypothesize that variance between individual anesthesia providers in the use of neuromuscular blocking drugs and reversal agents differs depending on provider type.
Interventions
- OTHER Neuromuscular blocking agents
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 265,537 participants |
| Start Date | 2018-06-29 |
| Est. Completion | 2021-03-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03585348
The ClinicalTrials.gov registry entry for NCT03585348 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 265,537 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Neuromuscular blocking agents is the first listed.
NCT03585348 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03585348 about?
NCT03585348 is a clinical study titled "Provider Variability in the Use of Neuromuscular Blocking Drugs and Reversal". The use of neuromuscular blocking agents during surgery is associated with postoperative respiratory complications and increased risk of readmission to the hospital following ambulatory surgery. Understanding the clinical behavior of providers is essential in devising and assessing quality improveme...
What is the current status of trial NCT03585348?
This trial is currently completed. The enrollment target is 265,537 participants. The study started on 2018-06-29. Estimated completion is 2021-03-31.
What interventions are being tested in trial NCT03585348?
The interventions under investigation include: Neuromuscular blocking agents (OTHER).
Who is sponsoring clinical trial NCT03585348?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.